1 Carapetis JR, Steer AC, Mulholland EK and M Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685–94.
2 Martin J. The Streptococcus pyogenes Carrier State, in Streptococcus pyogenes : Basic Biology to Clinical Manifestations, Ferretti JJ, Stevens DL, and Fischetti VA. Editors. 2016: Oklahoma City (OK).
3 Mearkle R, Saavedra-Campos M, Lamagni T, Usdin M, Coelho J, Chalker V, et al. Household transmission of invasive group A Streptococcus infections in England: a population-based study, 2009, 2011 to 2013. Euro Surveill, 2017;22(19).
4 Lancefield RC. A Serological Differentiation of Human and Other Groups of Hemolytic Streptococci. J Exp Med. 1933;57(4):571–95.
5 Fischetti VA, Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev. 1989;2(3):285–314.
6 Nizet V, Arnold JC. Streptococcus pyogenes (Group A Streptococcus), in Principles and Practices of Pediatric Infectious Diseases, Long S, Pickering LK, Prober CG. Editor. 2012, Elsevier: Philadelphia. 698–707.
7 Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, Henningham A, et al. Disease manifestations and pathogenic mechanisms of Group A Streptococcus. Clin Microbiol Rev. 2014;27(2):264–301.
8 Cole JN, Barnett TC, Nizet V and Walker MJ. Molecular insight into invasive group A streptococcal disease. Nat Rev Microbiol. 2011;9(10):724–36.
9 Brouwer S, Barnett TC, Rivera-Hernandez T, Rohde M and Walker MJ. Streptococcus pyogenes adhesion and colonization. FEBS Lett. 2016;590(21):3739–57.
10 Edwards RJ, Taylor GW, Ferguson M, Murray S, Rendell N, Wrigley A et al. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J Infect Dis. 2005;192(5):783–90.
11 Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan JT, Turner CE et al. The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe. 2008.4(2):170–8.
12 Timmer AM, Timmer JC, Pence MA, Hsu LC, Ghochani M, Frey TG, et al. Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis. J Biol Chem. 2009;284(2):862–71.
13 Uchiyama S, Andreoni F, Schuepbach RA, Nizet V and Zinkernagel AS. DNase Sda1 allows invasive M1T1 Group A Streptococcus to prevent TLR9-dependent recognition. PLoS Pathog. 2012;8(6):1002736.
14 Bisno AL, Brito MO and Collins CM. Molecular basis of group A streptococcal virulence. Lancet Infect Dis. 2003;3(4);191–200.
15 Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470–511.
16 Barnett TC, Liebl D, Seymour LM, Gillen CM, Lim J, Larock CN et al. The globally disseminated M1T1 clone of group A Streptococcus evades autophagy for intracellular replication. Cell Host Microbe. 2013;14(6):675–82.
17 Hertzen E, Johansson L, R. Wallin, H. Schmidt, M. Kroll, A.P. Rehn, et al., M1 protein-dependent intracellular trafficking promotes persistence and replication of Streptococcus pyogenes in macrophages. J Innate Immun. 2010;2(6):534–45.
18 Medina E, Goldmann O, Toppel AW and Chhatwal GS, Survival of Streptococcus pyogenes within host phagocytic cells: a pathogenic mechanism for persistence and systemic invasion. J Infect Dis. 2003;187(4):597–603.
19 Sumby P, Whitney AR, Graviss EA, DeLeo FR and Musser JM, Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2006;2(1):5.
20 Shaikh N, Swaminathan N and Hooper EG, Accuracy and precision of the signs and symptoms of streptococcal pharyngitis in children: a systematic review. J Pediatr, 2012;160(3):487–93 e3.
21 Wessels MR. Pharyngitis and Scarlet Fever, in Streptococcus pyogenes: Basic Biology to Clinical Manifestations, Ferretti JJ, Stevens DL, and Fischetti VA, Editors. 2016: Oklahoma City (OK).
22 Wu PC, Lo WT, Chen SJ and Wang CC, Molecular characterization of Group A streptococcal isolates causing scarlet fever and pharyngitis among young children: a retrospective study from a northern Taiwan medical center. J Microbiol Immunol Infect, 2014;47(4):304–10.
23 Centor RM, Witherspoon JM, Dalton HP, Brody CE and Link K, The diagnosis of strep throat in adults in the emergency room. Med Decis Making. 1981;1(3):239–46.
24 Fine AM, Nizet V and Mandl KD, Large-scale validation of the Centor and McIsaac scores to predict group A streptococcal pharyngitis. Arch Intern Med. 2012;172(11):847–52.
25 McIsaac WJ, White D, Tannenbaum D and Low DE, A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ. 1998;158(1):75–83.
26 Cohen JF, Bertille N, Cohen R and Chalumeau M, Rapid antigen detection test for group A streptococcus in children with pharyngitis. Cochrane Database Syst Rev. 2016;7:CD010502.
27 Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):1279–82.
28 Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009;119(11):1541–51.
29 Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC and Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis. 1996;23(5):1091–8.
30 Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999;318(7198):1591–4.
31 Inghammar M, Rasmussen M and Linder A, Recurrent erysipelas-risk factors and clinical presentation. BMC Infect Dis. 2014;14:270.
32 Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147–59.
33 Bryant AE, Bayer CR, Huntington JD and Stevens DL. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. J Infect Dis. 2006;193(12):1685–92.
34 Urschel JD. Necrotizing soft tissue infections. Postgrad Med J, 1999;75(889):645–9.
35 Carbonetti F, Cremona A, Carusi V, Guidi M, Iannicelli E, Di Girolamo M, et al., The role of contrast enhanced computed tomography in the diagnosis of necrotizing fasciitis and comparison with the laboratory risk indicator for necrotizing fasciitis (LRINEC). Radiol Med. 2016;121(2):106–21.
36 Bruun T, Kittang BR, de Hoog BJ, Aardal S, Flaatten HK, Langeland N. et al. Necrotizing soft tissue infections caused by Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis of groups C and G in western Norway. Clin Microbiol Infect. 2013;19(12):545–50.
37 Miller, A.T., P. Saadai, A. Greenstein and C.M. Divino, Postprocedural necrotizing fasciitis: a 10-year retrospective review. Am Surg. 2008;74(5):405–9.
38 Low DE. Toxic shock syndrome: major advances in pathogenesis, but not treatment. Crit Care Clin. 2013;29(3):651–75.
39 Carapetis JR, McDonald M and Wilson NJ, Acute rheumatic fever. Lancet. 2005;366(9480):155–68.
40 Ravisha MS, Tullu MS and Kamat J, Rheumatic fever and rheumatic heart disease: clinical profile of 550 cases in India. Arch Med Res. 2003;34(5):382–7.
41 Gewitz MH, Baltimore RS, Tani LY, Sable CA, Shulman ST, Carapetis J, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131(20):1806–18.
42 Kambham N. Postinfectious glomerulonephritis. Adv Anat Pathol. 2012;19(5):338–47.
43 Rodriguez-Iturbe B and Batsford S. Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int. 2007;71(11):1094–104.
44 Rodriguez-Iturbe B and Musser JM. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol. 2008;19(10):1855–64.
45 infect.ch. Infect by anresis.ch. 2018 [cited April 2, 2018. Available from: www.infect.info.
46 Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34(4):482–92.
47 Lamden KH. An outbreak of scarlet fever in a primary school. Arch Dis Child. 2011;96(4):394–7.
48 Prevention, C.f.D.C.a. Healthcare Infection Control Practices Advisory Committee (HICPAC). Available from: https://www.cdc.gov/hicpac/2007ip/2007ip_appenda.html.
49 Chalker V, Jironkin A, Coelho J, Al-Shahib A, Platt S, Kapatai G, et al. Genome analysis following a national increase in Scarlet Fever in England 2014. BMC Genomics. 2017;18(1):224.
50 Davies MR, Holden MT, Coupland P, Chen JH, Venturini C, Barnett TC, et al. Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nat Genet. 201547(1):84–7.
51 Andreoni F, Zurcher C, Tarnutzer A, Schilcher K, Neff A, Keller N, et al. Clindamycin Affects Group A Streptococcus Virulence Factors and Improves Clinical Outcome. J Infect Dis. 2016.
52 Eagle H.q. The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and Treponema pallidum. J Exp Med. 1949;90(6):595–607.
53 Stevens DL, Gibbons AE, Bergstrom R and Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158(1):23–8.
54 Alejandria MM, Lansang MA, Dans LF and Mantaring JB, 3rd, Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;(9):CD001090.
55 Schrag C, Kleger GR. Toxisches Schock Syndrom. Swiss Medical Forum. 2011;11(45):805–7.
56 Siegel J, Rhinehart E, Jackson M, Chiarello L and g.f.I.P. the Healthcare Infection Control Practices Advisory Committee. Preventing Transmission of Infectious Agents in Healthcare Settings. 2007; Available from: https://www.cdc.gov/infectioncontrol/guidelines/isolation/.
57 PIGS. Empfehlungen der pädiatrischen Infektiologieguppe der Schweiz zur Diagnose un Therapie von akuter Otitis media, Sinusitis, Pneumonie (community-acquired), Tonsillopharynitis beim Kind. 2010; Available from: http://www.pigs.ch/pigs/05-documents/doc/reco2010-d.pdf.
58 Wachtler H, Chenot JF, P. German Society of General and M. Family, [Guidelines for the management of sore throat from the German Society of General Practice and Family Medicine]. HNO. 2011;59(5):480–4.
59 Tarnutzer AA, Andreoni FF, Keller NN, Zürcher CC, Norrby-Tegund AA, Schuepbach RR, Zinkernagel AA. Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model. Clin Microbiol Infect. 2018 Jul 16. pii: S1198-743X(18)30522-6 [Epub ahead of print].
– Cole JN, Barnett TC, Nizet V, Walker MJ. Molecular insight into invasive group A streptococcal disease. Nat Rev Microbio. 2011;9(10):724–36.
– Fine AM, Nizet V, Mandl KD. Large-scale validation of the Centor and McIsaac scores to predict group A streptococcal pharyngitis. Arch Intern Med. 2012;172(11):847–52.
– Low DE. Toxic shock syndrome: major advances in pathogenesis, but not treatment. Crit Care Clin. 2013;29(3):651–75.
– Andreoni F, Zürcher C, Tarnutzer A, Schilcher K, Neff A, Keller N, et al. Clindamycin Affects Group A Streptococcus Virulence Factors and Improves Clinical Outcome. J Infect Dis. 2017;215(2):269–77.
– Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):1279–82.